Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.

Amitava Das, Priyabrata Mukherjee, Sumit K. Singla, Praveen Guturu, Megan C. Frost, Debabrata Mukhopadhyay, Vijay H. Shah, Chitta Ranjan Patra

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.

Original languageEnglish (US)
Number of pages1
JournalNanotechnology
Volume21
Issue number30
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Nanoconjugates
Nitric oxide
Silicon Dioxide
Gold
Nitric Oxide
Silica
Nanoparticles
Fabrication
Chemical activation
Liver
Nitric Oxide Donors
Cell proliferation
Spectroscopy
Transmission electron microscopy
Drug Delivery Systems
Hepatic Stellate Cells

ASJC Scopus subject areas

  • Bioengineering
  • Chemistry(all)
  • Materials Science(all)
  • Mechanics of Materials
  • Mechanical Engineering
  • Electrical and Electronic Engineering

Cite this

Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide. / Das, Amitava; Mukherjee, Priyabrata; Singla, Sumit K.; Guturu, Praveen; Frost, Megan C.; Mukhopadhyay, Debabrata; Shah, Vijay H.; Patra, Chitta Ranjan.

In: Nanotechnology, Vol. 21, No. 30, 01.01.2010.

Research output: Contribution to journalArticle

Das, Amitava ; Mukherjee, Priyabrata ; Singla, Sumit K. ; Guturu, Praveen ; Frost, Megan C. ; Mukhopadhyay, Debabrata ; Shah, Vijay H. ; Patra, Chitta Ranjan. / Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide. In: Nanotechnology. 2010 ; Vol. 21, No. 30.
@article{0f63167274d5434591785dcf16fcbac7,
title = "Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.",
abstract = "Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.",
author = "Amitava Das and Priyabrata Mukherjee and Singla, {Sumit K.} and Praveen Guturu and Frost, {Megan C.} and Debabrata Mukhopadhyay and Shah, {Vijay H.} and Patra, {Chitta Ranjan}",
year = "2010",
month = "1",
day = "1",
doi = "10.1088/0957-4484/21/30/305102",
language = "English (US)",
volume = "21",
journal = "Nanotechnology",
issn = "0957-4484",
publisher = "IOP Publishing Ltd.",
number = "30",

}

TY - JOUR

T1 - Fabrication and characterization of an inorganic gold and silica nanoparticle mediated drug delivery system for nitric oxide.

AU - Das, Amitava

AU - Mukherjee, Priyabrata

AU - Singla, Sumit K.

AU - Guturu, Praveen

AU - Frost, Megan C.

AU - Mukhopadhyay, Debabrata

AU - Shah, Vijay H.

AU - Patra, Chitta Ranjan

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.

AB - Nitric oxide (NO) plays an important role in inhibiting the development of hepatic fibrosis and its ensuing complication of portal hypertension by inhibiting human hepatic stellate cell (HSC) activation. Here we have developed a gold nanoparticle and silica nanoparticle mediated drug delivery system containing NO donors, which could be used for potential therapeutic application in chronic liver disease. The gold nanoconjugates were characterized using several physico-chemical techniques such as UV-visible spectroscopy and transmission electron microscopy. Silica nanoconjugates were synthesized and characterized as reported previously. NO released from gold and silica nanoconjugates was quantified under physiological conditions (pH = 7.4 at 37 degrees C) for a substantial period of time. HSC proliferation and the vascular tube formation ability, manifestations of their activation, were significantly attenuated by the NO released from these nanoconjugates. This study indicates that gold and silica nanoparticle mediated drug delivery systems for introducing NO could be used as a strategy for the treatment of hepatic fibrosis or chronic liver diseases, by limiting HSC activation.

UR - http://www.scopus.com/inward/record.url?scp=79952200328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952200328&partnerID=8YFLogxK

U2 - 10.1088/0957-4484/21/30/305102

DO - 10.1088/0957-4484/21/30/305102

M3 - Article

VL - 21

JO - Nanotechnology

JF - Nanotechnology

SN - 0957-4484

IS - 30

ER -